http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-112014032513-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3a9df6734836f928dbfa95a3bb31459c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5047 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 |
| filingDate | 2012-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d771fc4f12ebc7f88269bc6acc1382b9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_235c0f0db99ce012096c6d6b781453a0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22b6d123738a8de04b83a0bf59f241c0 |
| publicationDate | 2017-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-112014032513-A2 |
| titleOfInvention | fenofibrate formulation |
| abstract | fenofibrate dosage forms contain a plurality of beads or particles, where the beads or particles include a pharmaceutical composition comprising fenofibrate; from 0.3% to 10% by weight of the beads or particles of a surfactant; and from about 5% to about 15% by weight of the beads or particles of a water soluble or water dispersible cellulosic binder. the mass ratio of the drug to the binder in the dosage form is between 3.5: 1 and 4.5: 1; and the dosage form produces a first cmax in vivo which is between about 10% and about 50% higher than a comparative cmax produced by a comparative dosage form. the comparative dosage form comprises the drug and the binder in a ratio of between 5: 1 and 15: 1. "fenofibrate formulation" are various fenofibrate dosage forms containing a plurality of microspheres or particles, wherein the microspheres or particles include a pharmaceutical composition comprising fenofibrate; from 0.3% to 10% by weight of the microspheres or particles of a surfactant; and from about 5% to about 15% by weight of the microspheres or particles of a water-soluble or water-dispersible cellulosic binder. the mass ratio of the drug to the binder in the dosage form is between about 3.5: 1 and 4.5: 1; and the dosage form produces a first in vivo max which is between about 10% and about 50% greater than a comparative max. produced by a comparative dosage form. The comparative dosage form comprises the drug and the binder in a ratio of about 5: 1 to 15: 1. |
| priorityDate | 2012-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 21.